Corcept Therapeutics Inc

  • Earnings Score
  • Moat Score
  • Market Cap $7.36B
  • PE 56
  • Debt -
  • Cash $89.82M
  • EV -
  • FCF $177.16M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$132.51M
EBIT$136.12M
ROE19%
ROA16%
FCF$177.16M
Equity$683.29M
Growth Stability97%
PE55.53
PEG13.82
PB10.77
P/FCF41.53
P/S10.73
Price/Cash0.01
Net Margins13%
Gross Margins98%
Op. Margins20%
Earnings CAGR28%
Sales Growth YoY7%
Sales Growth QoQ-14%
Sales CAGR25%
FCF CAGR23%
Equity CAGR44%
Earnings Stability0.39
Earnings Growth YoY-26%
Earnings Growth QoQ-33%
Earnings CAGR 5Y4%
Sales CAGR 5Y16%
FCF CAGR 5Y-1%
Equity CAGR 5Y6%
Earnings CAGR 3Y26%
Sales CAGR 3Y26%
FCF CAGR 3Y9%
Equity CAGR 3Y17%
Market Cap$7.36B
Revenue$685.45M
Assets$846.46M
Cash$89.82M
Shares Outstanding104.11M
Earnings Score42%
Moat Score95%
Working Capital295.44M
Current Ratio3.07
Gross Profit$674.70M
Shares Growth 3y-1%
Equity Growth QoQ1%
Equity Growth YoY25%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

SEC Filings

Direct access to Corcept Therapeutics Inc (CORT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Corcept Therapeutics Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Corcept Therapeutics Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 28%
Stability 39%
loading chart...

Corcept Therapeutics Inc Discounted Cash Flow

Fully customizable DCF calculator online for Corcept Therapeutics Inc.

= $8.9B
012345678910TV
fcf$177M$218M$268M$330M$406M$500M$615M$757M$931M$1.1B$1.4B$14B
DCF$198M$222M$248M$277M$310M$347M$388M$435M$486M$544M$5.4B
Value$8.9B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-13%10%81%30%31%30%31%25%22%21%13%
ROA-15%24%29%28%23%29%20%20%19%16%
ROE-20%68%27%25%20%30%20%21%21%19%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-0.810--------
Debt over Equity3.240.350--------
Growth Stability---100%100%100%100%97%99%100%97%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-62%96%58%22%15%3%10%20%40%16%
Earnings YoY growth--227%1K%-42%25%13%6%-10%4%32%4%
Equity YoY growth-124%362%44%35%41%-28%34%1%34%6%
FCF YoY growth-485%233%91%17%12%11%-28%6%54%-1%